Opportunities for innovation in generic pharma products

1. Supercharge your business growth to outperform competitors using our custom business development
playbook and proprietary global marketing networks.
Innovation Ideas
Generic Prescription Drugs
Portfolio Consulting Services

2. Innovation Ideas
Introduction
The generic industry is changing rapidly; some markets are consolidating to cope with slowing growth, others are
exploding as population wealth rises.
Big pharma is now a major player in the generic sector. Governments are pushing through Rx to OTC switches in order
to reduce their drug budgets in chronic illnesses.
In fast growth markets, governments are creating protectionist environments, seeking to develop local manufacturing
whilst also ensuring they are not dependent on any particular country or company for imports.
All in all, to prosper in the generic industry of tomorrow, new ideas need to be considered.
This presentation is a simple report on ideas that Generic Pharma 2.0 have been asked to research by various clients.
A summary of differentiation possibilities, without consideration for technical or economic viability.
At Generic Pharma 2.0 we call this: Pharmagination.
Our contact details can be found at the end of this presentation; we’d love to run an ideation session with you.
Asa Cox, CEO & Founder

3. Summary
Patients
- Engagement, services, customisation
- Innovation requires commitment
Products
- World is oyster, blank canvass
- Innovation requires investment
Price
- Incremental, organisational
- Innovation requires scale
Partners
- Integration, co-invention, services
- Innovation requires collaboration

4. Patients
Dose Management/Compliance
- Data collection: Home dispensing recorders
- Monitoring: Patient communication systems/service
- Intelligent Packaging: Dose regimen notifications
- Reminders: Integrated with MHR, insurance, pharmacies
- Dispensing systems: Multi-drug machines
- Education: Content systems to reduce intentional non-adherence
- Labels: Clarity, Weight/dose information
- Engagement, services, customisation
- Innovation requires commitment

5. Patients
Safety
- Child & Geriatric best practice: pack design, readability
- Anti-counterfeiting: digital verification, hologram
- Dose form: stamps, coating, colour, taste
- Dosing: Part doses (also patient cost reduction)
- Abuse deterrents: Non-crushable, irritants, antidote combo, bio-activated
- Engagement, services, customisation
- Innovation requires commitment

6. Products
First to market
- Orphan drugs: new indication for old molecule (<clinical + >safety)
- Patent challenges: salts, alternative formulations (505b2), invalidity, data
mining, Canadian partner of choice
(Finances - litigation funding, at-risk launch insurance)
- Reformulation: SR/ER, Pegylation/Liposomes, >stability (global req.),
bioavailability (reduce volume), fast acting (ODT, thinstrip), solid to liquid, semi-
solid to patch/tape, phase release (early morning, mid sleep etc)
"Is it valuable to the patient, valuable to the physician or valuable to the health
providers/insurance companies"
- World is oyster, blank canvass
- Innovation requires investment

7. Products
Patient Centric
- Convenience:
Films, liquids, unit dose, direct-to-mouth, patch/tape
Regimen/patient packs (blisters vs bottles)
- Preference:
Foam or spray vs cream/gel/ointment
Size - "bigger is better" vs easy-to-swallow
- World is oyster, blank canvass
- Innovation requires investment

8. Price
R&D
- Optimisation (market vs manufacturing vs resources vs strategy)
- Venture capital/Darwinian view of project approval
Manufacturing
- Complexity/variant management (esp. with PSI):
Batch changes, packaging, stock etc
Regional packaging hubs for PSI
- Continuous manufacturing
- Manufacturing techniques
e.g Foam (vs wet) granulation
- Incremental, organisational
- Innovation requires scale

9. Price
Sourcing/Supply-Chain/Purchasing
- China/India sourcing office
- API R&D price reduction exchange for royalty
(subject to timetable, patents etc)
- Co-development (cost/profit sharing) for higher risk
(competition, time, costs, reg.)
- Co-invention projects for global exploitation
- Global benchmarking ('local' price = future regulated price)
- Sourcing/purchasing plaforms, e.g io-pharma.com
Organisation
- Outsource R&D for certain projects (sponsor/FTE projects)
- R&D organisation best practice for productivity (definition?)
- Incremental, organisational
- Innovation requires scale

10. Partners
International
- Patient services: improve awareness, loyalty, preference. 'Canada quality'
- Products: First to market, support 'early' launch (patent breaking)
- Price: Local 'manufacturing', regional CMO's (vs 'made in Canada'?)
Domestic
- Dis-intermediation (direct to pharmacy + support contract flexible buyers)
- Online pharmacy (direct to patient)
- Out of stock insurance (financial)
Both
- Anti-counterfeiting 'services'
- Pharmacy education (product reformulation, value add etc)
- Information for pharmacies (availability, new products, patents, promotions)
- Integration, co-invention, services
- Innovation requires collaboration

11. About GP2.0
Supercharge your business growth to
outperform competitors using our custom
business development playbook and
proprietary global marketing networks.
Masters of business development & marketing
“
”
Asa Cox, Founder & CEO
asa.cox@genericpharma20.com
+1 705 615 1500
Services
Outsourced Business Development
Business Development Planning & Strategy
In/Out Licensing & Partnership Selection
Consulting
Portfolio Development & Optimisation
International Market Entry Planning
Software/Web
Marketing Content Creation, Distribution & Monitoring
Lead Generation & Lead Conversion Software
Creative
Web & Print Design
Established in 2008, Generic Pharma 2.0 has
been building a global network of 30,000
companies; achieved by combining ferocious
business development and web technologies.
It offers clients both access to its network and the
intelligence gained from unique perspective.
We work with companies of all sizes, locations
and product categories. We partner with clients.
We create together. We have a lot of fun.
Lets start growing!